We
demonstrate that a novel functionalized interface, where molecularly
imprinted polymer nanoparticles (nanoMIPs) are attached to screen-printed
graphite electrodes (SPEs), can be utilized for the thermal detection
of the cardiac biomarker troponin I (cTnI). The ultrasensitive detection
of the unique protein cTnI can be utilized for the early diagnosis
of myocardial infraction (i.e., heart attacks), resulting in considerably
lower patient mortality and morbidity. Our developed platform presents
an innovative route to develop accurate, low-cost, and disposable
sensors for the diagnosis of cardiovascular diseases, specifically
myocardial infraction. A reproducible and advantageous solid-phase
approach was utilized to synthesize high-affinity nanoMIPs (average
size = 71 nm) for cTnI, which served as synthetic receptors in a thermal
sensing platform. To assess the performance and commercial potential
of the sensor platform, various approaches were used to immobilize
nanoMIPs onto thermocouples or SPEs: dip coating, drop casting, and
a covalent approach relying on electrografting with an organic coupling
reaction. Characterization of the nanoMIP-functionalized surfaces
was performed with electrochemical impedance spectroscopy, atomic
force microscopy, and scanning electron microscopy. Measurements from
an in-house designed thermal setup revealed that covalent functionalization
of nanoMIPs onto SPEs led to the most reproducible sensing capabilities.
The proof of application was provided by measuring buffered solutions
spiked with cTnI, which demonstrated that through monitoring changes
in heat transfer at the solid–liquid interface, we can measure
concentrations as low as 10 pg L–1, resulting in
the most sensitive test of this type. Furthermore, preliminary data
are presented for a prototype platform, which can detect cTnI with
shorter measurement times and smaller sample volumes. The excellent
sensor performance, versatility of the nanoMIPs, and reproducible
and low-cost nature of the SPEs demonstrate that this sensor platform
technology has a clear commercial route with high potential to contribute
to sustainable healthcare.